GB0905667D0 - Compounds for treatment of duchenne muscular dystrophy - Google Patents

Compounds for treatment of duchenne muscular dystrophy

Info

Publication number
GB0905667D0
GB0905667D0 GBGB0905667.2A GB0905667A GB0905667D0 GB 0905667 D0 GB0905667 D0 GB 0905667D0 GB 0905667 A GB0905667 A GB 0905667A GB 0905667 D0 GB0905667 D0 GB 0905667D0
Authority
GB
United Kingdom
Prior art keywords
compounds
treatment
muscular dystrophy
duchenne muscular
duchenne
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0905667.2A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Summit Therapeutics Ltd
Original Assignee
Summit Corp PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Summit Corp PLC filed Critical Summit Corp PLC
Priority to GBGB0905667.2A priority Critical patent/GB0905667D0/en
Publication of GB0905667D0 publication Critical patent/GB0905667D0/en
Priority to PCT/EP2009/065127 priority patent/WO2010112091A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB0905667.2A 2009-04-02 2009-04-02 Compounds for treatment of duchenne muscular dystrophy Ceased GB0905667D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0905667.2A GB0905667D0 (en) 2009-04-02 2009-04-02 Compounds for treatment of duchenne muscular dystrophy
PCT/EP2009/065127 WO2010112091A1 (en) 2009-04-02 2009-11-13 Compounds for treatment of duchenne muscular dystrophy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0905667.2A GB0905667D0 (en) 2009-04-02 2009-04-02 Compounds for treatment of duchenne muscular dystrophy

Publications (1)

Publication Number Publication Date
GB0905667D0 true GB0905667D0 (en) 2009-05-20

Family

ID=40749941

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0905667.2A Ceased GB0905667D0 (en) 2009-04-02 2009-04-02 Compounds for treatment of duchenne muscular dystrophy

Country Status (2)

Country Link
GB (1) GB0905667D0 (en)
WO (1) WO2010112091A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201412010D0 (en) 2014-07-04 2014-08-20 Summit Corp Plc Treatment of hypertransaminasemia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3158610A (en) * 1964-01-03 1964-11-24 American Cyanamid Co 2-styrylbenzoxazole brighteners
EP1986633B1 (en) * 2006-02-10 2014-07-30 Summit Corporation Plc Treatment of duchenne muscular dystrophy
JP2010535708A (en) * 2007-08-03 2010-11-25 ビオマリン アイジーエー リミテッド Drug combinations for the treatment of Duchenne muscular dystrophy
GB0715939D0 (en) * 2007-08-15 2007-09-26 Vastox Plc Method of treatment of duchenne muscular dystrophy

Also Published As

Publication number Publication date
WO2010112091A1 (en) 2010-10-07

Similar Documents

Publication Publication Date Title
GB0815369D0 (en) Compounds for treatment of duchenne muscular dystrophy
GB0821307D0 (en) Compounds for treatment of duchenne muscular dystrophy
GB0822981D0 (en) Compounds for treatment of duchenne muscular dystrophy
GB0715938D0 (en) Method of treatment of duchenne muscular dystrophy
IL228598A0 (en) Treatment of duchenne muscular dystrophy
RS55735B1 (en) Drug combinations for the treatment of duchenne muscular dystrophy
GB0715087D0 (en) Drug combinations for the treatment of duchenne muscular dystrophy
IL193314A0 (en) Treatment of duchenne muscular dystrophy
ME02347B (en) Rostafuroxine for pharmacogenomic treatment of cardiovascular conditions
ZA200806986B (en) Treatment of duchenne muscular dystrophy
GB0715939D0 (en) Method of treatment of duchenne muscular dystrophy
EP2576582A4 (en) Treatment of muscular dystrophy
GB0905664D0 (en) Compounds for treatment of duchenne muscular dystrophy
GB0905670D0 (en) Compounds for treatment of duchenne muscular dystrophy
GB0905667D0 (en) Compounds for treatment of duchenne muscular dystrophy
HK1178057A1 (en) Treatment of osteoporosis
GB0901417D0 (en) Compounds for treatment of duchenne muscular dystrophy
GB0902411D0 (en) Compounds for treatment of duchenne muscular dystrophy
GB0809314D0 (en) Compounds for treating muscular dystrophy
GB0901794D0 (en) Compounds for treating muscular dystrophy
GB0803906D0 (en) Compounds for treating duchenne muscular dystrophy
GB0807216D0 (en) Drug combination for the treatment of duchenne muscular dystrophy
GB0913427D0 (en) Compounds for treatment of imflammation
EG26997A (en) Tube for treatment of syrngomylia
GB0623985D0 (en) Treatment of duchenne muscular dystrophy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)